Hodgkin lymphoma (HL) is a rare B-cell malignancy that accounts for less than 1% of all cancers. Hodgkin lymphoma accounts for about 30% of all lymphomas.  The absolute incidence rate has remained the same over the years.  Generally, Hodgkin lymphoma originates in the lymph nodes, most commonly in the neck region, and spreads to adjacent lymph nodes.

Target Genes Delivered in vivo in Hodgkin's Lymphoma

Figure 1. The signaling of hodgkin's lymphoma.

Targeting studies of hodgkin's lymphoma therapy-related genes can be divided into two main categories: targeting the tumor microenvironment and HRS (Hodgkin and Reed/Sternberg cells, the hallmark cells of Hodgkin's lymphoma) cells.

Targeting Tumor Microenvironment Genes

In hodgkin's lymphom, HRS cells are surrounded by a massive infiltration of reactive cells. These reactive cells are not bystander cells but are participating cells that provide survival signals to HRS cells. Since HRS cells are difficult to grow in culture once they are removed from their microenvironment. Therefore, eliminating these reactive cells from the microenvironment may deprive HRS cells of key survival factors and may lead to their growth arrest and death. The study found that in the study of hodgkin's lymphom, CD20 and CD52 are the key genes targeting the microenvironment of hodgkin's lymphom.

Genes that Target HRS Cells

HRS cells express several receptors belonging to the tumor necrosis factor (INF) receptor family, including pro-survival receptors and pro-death receptors.  Pro-survival receptors have similar biological functions, including induction of cytokine and chemokine secretion, as well as activation of shared signaling pathways such as NF-KB, extracellular signal-regulated kinase (ERK)/mitogen-activated protein (MAP) kinase and phosphatidylinositol 3 (PI3)-kinase/Akt pathways. Studying the link between the function of these receptors and hodgkin's lymphom is a key idea in the search for treatment options.

The study found that the genes that are currently differentially expressed in HRS cells include: CD30, CD40, RANK & RANK ligand, B-cell activating factor (BAFF), TRAIL (Apo2L) & its receptors, IL-13 & IL-13 receptor, CD80, NF-κB, ERK/MAP kinase, PI3K/Akt/mTOR, HSP90 and etc..

In addition to the above genes, there are interesting hodgkin's lymphom -related genes that need to be explored and studied. Therefore, there is a need for an in vivo transfection system that can precisely target hodgkin's lymphom tissue and be taken up by tumor cells to function in vivo. The system can help researchers overcome various challenges encountered during in vivo transfection:

• Relevant molecular function studies can only be carried out in vitro, lacking important in vivo data
• Using in vitro transfection system for in vivo transfection, the transfection efficiency is very low;
• The in vivo transfection system used is not specific to hodgkin's lymphom tissues and cells, and is toxic to the body;
• The in vivo transfection system used cannot penetrate the hodgkin's lymphom tissue into the tumor tissue;
• The nucleic acid load of the in vivo transfection system is low, and it is difficult to achieve the expected effect;
• Etc…

Our Advantage:

• We can provide an in vivo transfection system for hodgkin's lymphom tissues and cells to achieve efficient transfection
• Our system can target multiple targets at the same time, improving targeting accuracy
• The in vivo transfection system has low toxicity to the body and is safe to use
• In vivo transfection system vectors can protect nucleic acids from degradation during in vivo delivery
• Persistent knockout effect in experimental animals after a single injection
• The system load is high, and the transfection needs of different doses can be completed
• Professional design and service team to provide you with reliable service and technical support
• Timely feedback of technical reports

CD BioSciences specializes in developing transfection systems and customizing transfection reagents for gene transfection using our core technologies. With our high-quality products and services, your transfection results can be greatly improved. If you can't find a perfect in vivo transfection system, you can contact us. We can provide one-to-one personal customization service.

References

1. Yazbeck V, et al.; Hodgkin's lymphoma: molecular targets and novel treatment strategies. Future Oncol. 2006, 2(4):533-51.
2. Fiumara P, et al.; Functlonal expression of receptor activator of nuclear factor-kB in Hodgkin's disease cell lines. Blood. 2001, 98, 2784-2790.
3. Younes A, Carbone A. Clinicopathologic and molecular features of Hodgkin's lymphoma. Cancer Biol. Ther. 2003, 2, 500-507.
4. Rehwald U, et al.; Treatment of relapsed CD20+ Hodgkin's lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a Phase II trial of the German Hodgkin's Lymphoma Study Group. Blood. 2003, 101, 420-424
5. Ravandi F, O'Brien S. Alemtuzumab. Expert Rev. Anticancer Ther. 2005, 5, 39-51.
6. Younes A, et al.; Nuclear transcription factor-kB in Hodgkin's disease. Leuk. Lymphoma. 2003, 44, 929-935.

* For research use only. Not for use in clinical diagnosis or treatment of humans or animals.